Sign in

CIK 0000908259 · Non-accelerated filer<br>Smaller reporting company

Oncotelic Therapeutics, Inc.

Sign in to watch
Ticker
OTLC
Exchange
OTC
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
133679168
Phone
650-635-7000
Business address
29397 AGOURA RD., #107, AGUORA HILLS, CA, 91301
Former names
MATEON THERAPEUTICS INC, OXIGENE INC
  1. 4 Open-market buy CHAIRMAN AND CEO bought 126,888 shares at $0.03 ($4,327)
  2. 4 Open-market buy CHAIRMAN AND CEO bought 100,000 shares at $0.05 ($4,500)
  3. 4 Open-market buy CHAIRMAN AND CEO bought 120,000 shares at $0.05 ($6,000)
  4. 4 Open-market buy CHAIRMAN AND CEO bought 70,000 shares at $0.08 ($5,600)
  5. 4 Open-market buy CHAIRMAN AND CEO bought 20,000 shares at $0.07 ($1,360)
  6. 4 Open-market buy CHAIRMAN AND CEO bought 80,000 shares at $0.08 ($6,560)
  7. 4 Derivatives Options or other derivatives
  8. 4 Derivatives Options or other derivatives
  9. 4 Derivatives Options or other derivatives
  10. 4 Derivatives Options or other derivatives
  11. 4 Conversion CHIEF CLINICAL OFFICER acquired 938,646 shares (conversion)
  12. 4 Grant or award CHAIRMAN AND CEO acquired 259,302 shares (grant or award)
  13. 4 Conversion Director acquired 3,291,720 shares (conversion)
  14. 4 Grant or award CHIEF FINANCIAL OFFICER acquired 298,837 shares (grant or award)
  15. 4 Derivatives Options or other derivatives
  16. 4 Grant or award CHIEF BUSINESS OFFICER acquired 102,519 shares (grant or award)
  17. 4 Open-market buy CHIEF FINANCIAL OFFICER bought 60,000 shares at an average $0.19 ($11,558)
  18. 4 Open-market buy CHIEF TECHNOLOGY OFFICER bought 22,173 shares at $0.18 ($4,098)
  19. 4 Open-market buy CHIEF EXECUTIVE OFFICER bought 50,500 shares at $0.19 ($9,595)
  20. 3 Insider Initial Statement of Ownership

Page 2 of 17 · 325 filings